Aaron N. Hendizadeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aaron N. Hendizadeh has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- David E. Kurlander
Division of Plastic and Reconstructive Surgery, RUSH University, Chicago, IL, USA
2 shared publications - George Kokosis
Department of Surgery, Division of Plastic and Reconstructive Surgery, Rush University Medical Center, Chicago, IL
2 shared publications Lauren Martin
Division of Plastic and Reconstructive Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL, USA
2 shared publicationsAdrian Markewych
Rush Medical College of Rush University, Chicago, IL, United States
1 shared publicationAmy Wen
Division of Plastic and Reconstructive Surgery, Department of Surgery Rush University Medical Center Chicago Illinois USA
1 shared publicationAndrea Madrigrano
Division of Surgical Oncology, Department of Surgery Rush University Medical Center Chicago Illinois USA
1 shared publication
Latest Publications
- 24 May 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (2) , 203-211
The Impact of Breast Reconstruction on Smoking Cessation Among Patients With Breast Cancer
Background and Objectives: In this study, we aim to evaluate trends in smoking cessation among breast cancer patients, with a particular focus on the impact of breast reconstruction surgery, and to assess if breast reconstruction surgery represents a unique opportunity for intervention. Methods: We performed a retrospective analysis of active smokers with a new diagnosis of breast cancer who were treated with any surgical or non‐surgical intervention at our institution between 2015 and 2024. Quitting was defined as continuous cessation for at least 30 days. Patients who quit were followed for at least 6 months after cessation. Results: One hundred twenty‐seven patients were identified. Mean age was 56 years (range 35–87). Eighty patients (63%) underwent surgery without reconstruction, 26 patients (20%) underwent surgery with reconstruction, and 21 patients (17%) received non‐surgical treatment only. Overall, 26% (34/127) of patients quit smoking. Among patients undergoing surgical treatment, patients undergoing reconstruction were significantly more likely to quit smoking than those without reconstruction (50% [13/26] vs. 23% [18/80]; p = 0.007). Patients receiving reconstruction were also significantly more likely to quit preoperatively (77% [10/13] vs. 33% [12/18]; p = 0.048). Median time from initial visit with surgical oncology to surgery was longer among reconstructive patients who quit pre‐operatively (90.5 days [IQR: 44–164]) than those who quit post‐operatively or did not quit (45 days [IQR: 26–68]; p = 0.13). Conclusions: Patients receiving breast reconstruction are significantly more likely to quit smoking than those who do not. Longer median time to surgery among patients who quit pre‐operatively emphasizes the need for targeted cessation interventions that allow for timely oncologic care.
- 24 May 2026
- Published by Wiley in Journal of Surgical Oncology
- Vol. 134 (2) , 203-211
The Impact of Breast Reconstruction on Smoking Cessation Among Patients With Breast Cancer
Background and Objectives: In this study, we aim to evaluate trends in smoking cessation among breast cancer patients, with a particular focus on the impact of breast reconstruction surgery, and to assess if breast reconstruction surgery represents a unique opportunity for intervention. Methods: We performed a retrospective analysis of active smokers with a new diagnosis of breast cancer who were treated with any surgical or non‐surgical intervention at our institution between 2015 and 2024. Quitting was defined as continuous cessation for at least 30 days. Patients who quit were followed for at least 6 months after cessation. Results: One hundred twenty‐seven patients were identified. Mean age was 56 years (range 35–87). Eighty patients (63%) underwent surgery without reconstruction, 26 patients (20%) underwent surgery with reconstruction, and 21 patients (17%) received non‐surgical treatment only. Overall, 26% (34/127) of patients quit smoking. Among patients undergoing surgical treatment, patients undergoing reconstruction were significantly more likely to quit smoking than those without reconstruction (50% [13/26] vs. 23% [18/80]; p = 0.007). Patients receiving reconstruction were also significantly more likely to quit preoperatively (77% [10/13] vs. 33% [12/18]; p = 0.048). Median time from initial visit with surgical oncology to surgery was longer among reconstructive patients who quit pre‐operatively (90.5 days [IQR: 44–164]) than those who quit post‐operatively or did not quit (45 days [IQR: 26–68]; p = 0.13). Conclusions: Patients receiving breast reconstruction are significantly more likely to quit smoking than those who do not. Longer median time to surgery among patients who quit pre‐operatively emphasizes the need for targeted cessation interventions that allow for timely oncologic care.
- 17 April 2025
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 105, 185-188
Evaluating Google Gemini’s AI generated responses to questions after breast reconstruction
- 17 April 2025
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 105, 185-188
Evaluating Google Gemini’s AI generated responses to questions after breast reconstruction
- Open Access
- 8 January 2025
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 7, ojaf037
Intercostal Regenerative Peripheral Nerve Interface for the Prevention of Neuroma-Associated Postbreast Surgery Pain Syndrome in Breast Reconstruction: A Proof-of-Concept Study
Postbreast surgery pain syndrome (PBSPS) represents chronic, persistent pain after breast surgery, which occurs in 13% to 60% of patients. Intercostal neuroma formation is one cause of PBSPS. Treatment of neuroma-related PBSPS with regenerative peripheral nerve interfaces (RPNI) has been demonstrated; however, prevention of PBSPS has not. The authors of this report aim to evaluate whether intercostal nerve RPNI prevents PBSPS in patients undergoing mastectomy with breast reconstruction. Consecutive patients who underwent a mastectomy and breast reconstruction with intercostal nerve RPNI attempted were included. RPNI was performed using a nearby pectoralis, intercostal, or serratus muscle graft. The primary outcome was postoperative intercostal neuroma-related PBSPS. This was defined by pain with location on the lateral chest wall, neuropathic quality, moderate severity, presence >50% of the time, and for >6 months. Twelve patients (19 breasts) were included. The median age was 54.7 years. Intercostal nerve RPNI was attempted for each breast and was achieved in 17 of 19 breasts (89.5%). In 2 breasts, no intercostal nerve could be identified. Surveys were completed by 9 patients (75.0%). One patient, with unilateral reconstruction, developed PBSPS (5.3% [1/19] of mastectomies, 8.3% [1/12] of patients). Complications included surgical-site cellulitis in 5.3% (1/19 breasts) and seroma in 31.6% (6/19 breasts). The median follow-up period was 19.0 months. The authors report a low rate of intercostal neuroma-related PBSPS after prophylactic intercostal RPNI. Because of the small sample size, further study is required to determine the contribution of neuroma formation to the overall incidence of PBSPS, and the efficacy of RPNI to prevent it. Level of Evidence: 4 (Therapeutic)
- 8 January 2025
- Published by Oxford University Press (OUP) in Aesthetic Surgery Journal Open Forum
- Vol. 7, ojaf037
Open AccessIntercostal Regenerative Peripheral Nerve Interface for the Prevention of Neuroma-Associated Postbreast Surgery Pain Syndrome in Breast Reconstruction: A Proof-of-Concept Study
Postbreast surgery pain syndrome (PBSPS) represents chronic, persistent pain after breast surgery, which occurs in 13% to 60% of patients. Intercostal neuroma formation is one cause of PBSPS. Treatment of neuroma-related PBSPS with regenerative peripheral nerve interfaces (RPNI) has been demonstrated; however, prevention of PBSPS has not. The authors of this report aim to evaluate whether intercostal nerve RPNI prevents PBSPS in patients undergoing mastectomy with breast reconstruction. Consecutive patients who underwent a mastectomy and breast reconstruction with intercostal nerve RPNI attempted were included. RPNI was performed using a nearby pectoralis, intercostal, or serratus muscle graft. The primary outcome was postoperative intercostal neuroma-related PBSPS. This was defined by pain with location on the lateral chest wall, neuropathic quality, moderate severity, presence >50% of the time, and for >6 months. Twelve patients (19 breasts) were included. The median age was 54.7 years. Intercostal nerve RPNI was attempted for each breast and was achieved in 17 of 19 breasts (89.5%). In 2 breasts, no intercostal nerve could be identified. Surveys were completed by 9 patients (75.0%). One patient, with unilateral reconstruction, developed PBSPS (5.3% [1/19] of mastectomies, 8.3% [1/12] of patients). Complications included surgical-site cellulitis in 5.3% (1/19 breasts) and seroma in 31.6% (6/19 breasts). The median follow-up period was 19.0 months. The authors report a low rate of intercostal neuroma-related PBSPS after prophylactic intercostal RPNI. Because of the small sample size, further study is required to determine the contribution of neuroma formation to the overall incidence of PBSPS, and the efficacy of RPNI to prevent it. Level of Evidence: 4 (Therapeutic)
- 24 December 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 101, 174-177
No penalty for blocking: Preoperative nerve blocks do not prevent motor nerve stimulation during TMR
- 24 December 2024
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 101, 174-177
No penalty for blocking: Preoperative nerve blocks do not prevent motor nerve stimulation during TMR